Among the 387 abstracted records, 118 (30.5%) received both GC and early IFN therapy, which has been defined empirically as initiation of IFN therapy within 5 days after admission and was shown to be associated with reduced mortality of COVID-19,23 95 (24.5%) received GC alone, 87 (22.5%) received early IFN therapy alone, and 87 (22.5%) received neither drugs. The gene discussed is IFNA1; the disease is COVID-19.